文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

RTOG 0126随机试验中单纯外照射放疗前列腺癌患者晚期毒性的条件风险及预测因素

Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-06-01

随着无毒性生存时间延长,2级及以上泌尿或胃肠毒性后续5年风险逐渐降低。基线尿路功能障碍、剂量提升与晚期泌尿毒性增加相关,急性胃肠毒性和剂量提升与晚期胃肠毒性增加相关,调强放疗与两种毒性风险降低相关。

要点

  • 入组时未来5年2级及以上泌尿毒性风险为9.57%,胃肠毒性风险为17.89%。
  • 无毒性生存5年后,后续5年2级及以上泌尿毒性风险降至3.02%,胃肠毒性降至1.54%。
  • 基线尿路功能障碍和剂量提升放疗与晚期泌尿毒性增加相关,调强放疗与两种毒性风险降低相关。

核心结论

  • 随着患者治疗后无毒性生存时间延长,2级及以上泌尿或胃肠毒性的条件风险逐渐降低,大多数毒性发生在治疗完成后最初几年。
  • 基线患者和治疗特征在入组时及后续时间点均与晚期毒性相关。

研究设计与样本

  • 患者按机构惯例接受三维适形放疗或调强放疗,未加用雄激素剥夺治疗,随机接受标准剂量70.2 Gy或剂量提升79.2 Gy前列腺单纯放疗,采用标准分割。
  • 采用单因素和多因素分析评估初始因素在治疗时及后续时间点对晚期毒性的预测价值。

主要发现

  • 入组时未来5年发生2级及以上泌尿毒性风险为9.57%,胃肠毒性风险为17.89%。
  • 无毒性生存5年后,后续5年发生2级及以上泌尿毒性风险为3.02%,胃肠毒性风险为1.54%。
  • 基线尿路功能障碍和剂量提升放疗与晚期泌尿毒性增加相关。
  • 急性胃肠毒性和剂量提升放疗与晚期胃肠毒性风险增加相关。
  • 调强放疗与两种毒性风险降低相关。

关键数值与推荐

  • 标准剂量放疗为70.2 Gy,剂量提升放疗为79.2 Gy,均针对前列腺单纯照射,标准分割。
  • 入组时未来5年2级及以上泌尿毒性风险9.57%,胃肠毒性风险17.89%。
  • 无毒性生存5年后后续5年2级及以上泌尿毒性风险3.02%,胃肠毒性风险1.54%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to characterize the conditional risk of developing grade 2+ urinary or gastrointestinal (GI) toxicity for patients treated with external beam radiation therapy in Radiation Therapy Oncology Group 0126. A secondary objective was to analyze baseline patient and treatment characteristics and determine their relevance in predicting toxicity both at the time of trial enrollment and at later points of follow-up. METHODS AND MATERIALS: One thousand five hundred thirty-two patients with localized prostate cancer were enrolled between March 2002 and August 2008, of whom 1499 were eligible and included in data analysis with a median follow-up of 8.4 years (range, 0.02-13 years). Patients were treated with either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy according to institutional practice without the addition of androgen deprivation and randomized to receive either standard-dose radiation therapy of 70.2 Gy or dose-escalated radiation therapy of 79.2 Gy of radiation therapy to the prostate only with standard fractionation. Univariate and multivariate analyses were performed to determine whether initial factors were predictive of late toxicity at the time of treatment and at later time points. RESULTS: As patients proceed further from completion of radiation therapy without the development of toxicity, the subsequent risk of both grade 2+ genitourinary (GU) and GI toxicity decreases with time. At the time of enrollment, the risk of developing grade 2+ toxicity over the next 5 years was 9.57% and 17.89%, respectively. After 5 years of toxicity-free survival, the risk of developing grade 2+ GU or GI toxicity in the subsequent 5 years was 3.02% and 1.54%, respectively. Baseline treatment and patient-related factors predicted late toxicity both at trial enrollment and after 2 years of toxicity-free survivorship. Baseline urinary dysfunction and dose-escalated radiation therapy were associated with increased late GU toxicity. Acute GI toxicity and dose-escalated radiation therapy were associated with increased risk of late GI toxicity. Treatment with intensity-modulated radiation therapy was associated with reduced risk of either toxicity. CONCLUSIONS: The conditional risk of grade 2+ toxicities decreases as patients proceed further from treatment, with most toxicities occurring in the first few years after treatment completion. Baseline patient and treatment characteristics remain relevant at both enrollment and later time points.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Alexander GS, Krc RF, Assif JW, et al. Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126. Int J Radiat Oncol Biol Phys. 2024. PMID: 38825251. doi:10.1016/j.ijrobp.2024.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。